Citadel Advisors
NAVB

Citadel Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Citadel Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-300
Closed -$78 – 15792
2023
Q1 		$78 Buy
300
+100
+50% +$29 ﹤0.01% 14596
2022
Q4 		$42 Buy
+200
New +$50 ﹤0.01% 14790
2022
Q3 		– Sell
-11,200
Closed -$8K – 14318
2022
Q2 		$8K Sell
11,200
-2,900
-21% -$2.46K ﹤0.01% 12643
2022
Q1 		$11K Sell
14,100
-21,700
-61% -$19.9K ﹤0.01% 13376
2021
Q4 		$36K Buy
35,800
+700
+2% +$985 ﹤0.01% 13413
2021
Q3 		$61K Buy
35,100
+3,700
+12% +$6.23K ﹤0.01% 13260
2021
Q2 		$57K Buy
31,400
+8,000
+34% +$14.1K ﹤0.01% 13283
2021
Q1 		$47K Sell
23,400
-13,400
-36% -$31.4K ﹤0.01% 12932
2020
Q4 		$79K Buy
36,800
+17,100
+87% +$40.3K ﹤0.01% 10354
2020
Q3 		$53K Buy
+19,700
New +$70.7K ﹤0.01% 9586
2017
Q3 		– Sell
-1,005
Closed -$10K – 8361
2017
Q2 		$10K Sell
1,005
-1,000
-50% -$9.89K ﹤0.01% 7374
2017
Q1 		$23K Buy
+2,005
New +$22.8K ﹤0.01% 7222
2016
Q4 		– Sell
-1,125
Closed -$21K – 8180
2016
Q3 		$21K Buy
1,125
+170
+18% +$2.15K ﹤0.01% 7035
2016
Q2 		$10K Buy
+955
New +$18.8K ﹤0.01% 6727
2016
Q1 		– Sell
-205
Closed -$5K – 8611
2015
Q4 		$5K Sell
205
-15
-7% -$521 ﹤0.01% 8465
2015
Q3 		$10K Buy
+220
New +$8.29K ﹤0.01% 8479
2015
Q1 		– Sell
-230
Closed -$9K – 9014
2014
Q4 		$9K Sell
230
-75
-25% -$2.06K ﹤0.01% 8167
2014
Q3 		$8K Buy
305
+205
+205% +$5.42K ﹤0.01% 7818
2014
Q2 		$3K Sell
100
-40
-29% -$1.29K ﹤0.01% 7810
2014
Q1 		$5K Sell
140
-595
-81% -$22.6K ﹤0.01% 7658
2013
Q4 		$30K Buy
735
+140
+24% +$5.48K ﹤0.01% 6282
2013
Q3 		$32K Sell
595
-1,095
-65% -$63.8K ﹤0.01% 6012
2013
Q2 		$90K Buy
+1,690
New +$84.4K ﹤0.01% 5303

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Citadel Advisors's NAVB Position: Q2 2023 in Review

Citadel Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 65,807 shares — an estimated $17.1K sold.

Citadel Advisors first reported a position in NAVB in Q2 2013 and held it in 35 quarters. The position peaked at $178K in Q4 2014. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Citadel Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 65,807 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $17.1K.
  • Citadel Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 35 quarters.
  • Citadel Advisors's Navidea Biopharmaceuticals Inc. position peaked at $178K in Q4 2014.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.